Deep search
Search
Images
Copilot
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Mounjaro vs. Ozempic: Which One Is Best for Me to Try for Weight Loss in 2025?
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help patients with type 2 diabetes manage blood sugar.
Not just weight loss, GLP-1 drugs like Ozempic can help with 175 conditions; says groundbreaking study
A discovery reveals that weight loss drugs like Ozempic and Mounjaro can positively impact 175 diseases and conditions beyond their primary uses. This includes unexpected benefits such as aiding in blood clotting and infections,
Ozempic: Weight-Loss Drug's Benefits And Risks Revealed in New Study
A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing them as miracle drugs.
Weight-loss drugs linked to benefits beyond dropping pounds
A new study published in the Nature Medicine monthly journal highlights the benefits and risks of weight-loss drugs like Ozempic and Wegovy. Positives include reduced risks of infections and cardiac arrest,
Weight-Loss Drugs Like Ozempic Linked To Lower Risk Of 42 Conditions
Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.
GLP-1 drugs like Ozempic and Wegovy lower the risk of 42 conditions
The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an assessment of how the drugs affect 175 conditions
10h
on MSN
Massive new study finds drugs like Ozempic affect 175 conditions — including a few surprises
A comprehensive new study supports evidence of the myriad health benefits of GLP-1 medications like Ozempic and Mounjaro — ...
decrypt
6h
Landmark Study Reveals New Benefits and Risks of Obesity Drugs Like Ozempic
A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss ...
5h
on MSN
The Ozempic debate: Large study reveals the good and the bad
A new study shows that GLP-1 drugs offer health benefits such as reducing risks for heart disease but also carry potential ...
4h
Study ties Ozempic-like drugs to dozens of benefits and risks
Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing dozens of health conditions. But the semaglutide-like drugs also appear to ...
1d
on MSN
Ozempic May Damage Vital Organs, Study Finds
An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...
16h
on MSN
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
12d
on MSN
How Dolores Catania, 54, Lost 20 Pounds With Ozempic, Diet, And Exercise
Dolores was one of the first Real Housewives stars to open up about using weight-loss drugs. In 2023, she told The Sun that ...
4d
on MSN
Ozempic and Wegovy selected for next round of Medicare drug price negotiations
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...
4d
on MSN
Ozempic among drugs selected for Medicare price negotiations as Biden exits
Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...
4d
Meet ‘Super’ Ozempic: Higher Dose Semaglutide Leads to Even Greater Weight Loss In Major Trial
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback